Active substance
Results for the substance ibrutinib
5 results
About this active substance
Ibrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor used to treat certain types of hematologic cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström’s macroglobulinemia. It works by blocking BTK, an enzyme essential for the survival and proliferation of cancer cells.
It is taken orally and is preferred in many cases due to its effectiveness and safety profile compared to conventional therapies.
Ibrutinib significantly improves survival rates in CLL patients and is more effective than traditional treatments such as combination chemotherapy. It is also used as a first-line treatment for certain lymphomas.
However, it can cause side effects, including bleeding, hypertension, arrhythmias, and an increased risk of infections.
It is taken orally and is preferred in many cases due to its effectiveness and safety profile compared to conventional therapies.
Ibrutinib significantly improves survival rates in CLL patients and is more effective than traditional treatments such as combination chemotherapy. It is also used as a first-line treatment for certain lymphomas.
However, it can cause side effects, including bleeding, hypertension, arrhythmias, and an increased risk of infections.
-
-
IMBRUVICA 420mg film-coated tablets CILAG ORIGINAL MEDICINE
-
IMBRUVICA 280mg film-coated tablets CILAG ORIGINAL MEDICINE
-
IMBRUVICA 140mg film-coated tablets CILAG ORIGINAL MEDICINE
-
IMBRUVICA 140mg capsules CILAG ORIGINAL MEDICINE